This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • HIV/AIDS  • Alert me on articles by topic

The Antiretroviral Therapy Cohort Collaboration*

Arch Intern Med. 2005;165:416-423.

Background  Although the incidence of most AIDS events declines after initiation of highly active antiretroviral therapy (HAART), this decline is more rapid for some conditions than others. We herein describe the decline in incidence of AIDS-defining events among 12 574 antiretroviral-naive individuals who started HAART in the Antiretorviral Therapy Cohort Collaboration and determined whether the rate of decline is similar for events with different etiologies.

Methods  Rates of AIDS were calculated for the periods 0 to 3, 4 to 6, 7 to 12, 13 to 24, and 25 to 36 months after starting HAART. Changes in incidence over time were investigated using Poisson regression.

Results  During 22 958 person-years of follow-up, 928 AIDS events developed (25.3% viral, 24.6% bacterial, 20.7% fungal, 8.1% protozoal, and 21.2% other). The incidence of any AIDS event declined from 129.3 (95% confidence interval [CI], 116.7-141.8) per 1000 person-years in the first 3 months to 13.2 (95% CI, 9.4-17.0) in the third year after starting HAART (P<.001). The rate of decline in incidence was greatest for events with a viral etiology (87.0% per year) and lowest for those with a fungal etiology (54.0% per year). In the third year, fungal events represented 37.0% of AIDS events that occurred. After adjustment for the CD4 count and human immunodeficiency virus 1 RNA level, changes in the incidence of bacterial and viral events from months 0 to 6 and 7 to 12 remained significant, suggesting that changes in these markers did not fully explain the changes in incidence seen.

Conclusion  Although the incidence of all AIDS-defining events decreased substantially after starting HAART, the pattern of decline was most pronounced for events with a viral etiology.

*Authors: The Writing Committee members for the Antiretroviral Therapy Cohort Collaboration are Antonella d’Arminio Monforte, MD, Caroline A. Sabin, PhD, Andrew Phillips, PhD, Jonathan Sterne, PhD, Margaret May, PhD, Amy Justice, PhD, Francois Dabis, PhD, Sophie Grabar, PhD, Bruno Ledergerber, PhD, John Gill, MBChB, Peter Reiss, PhD, and Matthias Egger, MD, MSc.
Group Information: A full listing of all study centers and collaborators of the Antiretroviral Therapy Cohort Collaboration was published previously (http://www.art-cohort-collaboration.org and Lancet. 1998;351:543-549 [http://www.lancet.com]).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Gastrointestinal complications of HIV infection: changing priorities in the HAART era
Wilcox and Saag
Gut 2008;57:861-870.
ABSTRACT | FULL TEXT  

Microalbuminuria associated with indicators of inflammatory activity in an HIV-positive population
Baekken et al.
Nephrol Dial Transplant 2008;0:gfn236v1-gfn236.
ABSTRACT | FULL TEXT  

CD4+ Count-Guided Interruption of Antiretroviral Treatment
The Strategies for Management of Antiretroviral Th
NEJM 2006;355:2283-2296.
ABSTRACT | FULL TEXT  

Differential Impact of Combination Antiretroviral Therapy in Preventing Kaposi's Sarcoma With and Without Visceral Involvement
Grabar et al.
JCO 2006;24:3408-3414.
ABSTRACT | FULL TEXT